Hypothesis

Chronic administration of beta-glucan induces a long‑lasting trained monocyte phenotype that simultaneously repairs intestinal barrier dysfunction and shifts microglia toward a protective state, thereby breaking the inflammaging loop that drives cognitive decline.

Mechanistic Insight Beyond Current Data

Beta-glucan‑induced H3K4me3/H3K27ac modifications not only boost IL‑1 responsiveness but also endow monocytes with a stable transcriptional program for high IL‑10 and TGF‑β secretion. These cytokines act in two parallel ways:

• In the gut, IL‑10/TGF‑β activate STAT3 in intestinal epithelial cells, upregulating tight‑junction proteins (occludin, claudin‑1) and mucin‑2, reducing permeability and limiting systemic influx of age‑associated glycation end‑products (AGEs).
• In the brain, trained monocytes that cross a temporarily compromised vasculature or patrol the meninges release IL‑10 and TGF‑β that bind microglial receptors, driving a shift toward a homeostatic phenotype (lower CD68, higher P2RY12) and suppressing NF‑κB–mediated neuroinflammation.

Because enteric macrophages and microglia share neuron‑crosstalk pathways, monocyte‑derived signals can synchronize peripheral and central immune niches, turning a bidirectional "mess" into a coordinated anti‑inflammatory circuit.

Testable Predictions

1. Aged mice receiving beta-glucan will show increased H3K4me3/H3K27ac at Il10 and Tgfb loci in circulating Ly6C^hi monocytes after 2 weeks, persisting for at least 8 weeks post‑treatment.
2. These mice will exhibit reduced serum FITC‑dextran leakage, lower circulating AGEs, and restored colonic tight‑junction expression compared with vehicle controls.
3. Brain immunohistochemistry will reveal a significant decrease in microglial CD68^+ area and an increase in P2RY12^+ density in the hippocampus and cortex.
4. Concurrently, beta‑glucan‑treated aged mice will perform better in spatial memory tasks (Morris water maze) and show improved long‑term potentiation in hippocampal slices.
5. Depletion of CCR2^+ monocytes (using anti‑CCR2 antibody) prior to beta‑glucan treatment will abolish the gut barrier and microglial improvements, confirming monocyte dependence.

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice (n=10 per group). Groups: (1) vehicle, (2) beta‑glucan (1 mg/mL in drinking water, 8 weeks), (3) beta‑glucan + CCR2 blockade, (4) young (3‑month) controls.
• Readouts:
  • Monocyte epigenetics: ChIP‑seq for H3K4me3/H3K27ac on Il10, Tgfb, Il1b promoters (sorted Ly6C^hi monocytes).
  • Gut permeability: FITC‑dextran (4 kDa) oral gavage, serum fluorescence quantification.
  • Barrier markers: qPCR/Western for occludin, claudin‑1, mucin‑2 in colonic epithelium.
  • Systemic inflammation: ELISA for serum AGEs, IL‑6, TNF‑α.
  • Microglial phenotype: Iba1/CD68/P2RY12 immunostaining, morphometric analysis.
  • Cognition: Morris water maze acquisition and probe trials; hippocampal slice LTP.
• Statistical plan: Two‑way ANOVA with factors treatment and age, followed by Tukey’s post‑hoc; significance set at p<0.05.

Potential Outcomes and Interpretation

If predictions hold, the data would support a model where epigenetically trained monocytes act as a "remote‑control" unit that rescues both sides of the gut‑brain axis, directly linking trained immunity to longevity‑relevant phenotypes. Failure to observe monocyte‑dependent improvements would challenge the sufficiency of peripheral myeloid reprogramming and suggest that additional cellular mediators (e.g., innate lymphoid cells) or neural pathways are required.

This hypothesis is falsifiable: a clear set of measurable molecular, physiological, and behavioral endpoints can confirm or refute the proposed monocyte‑mediated gut‑brain reset in aging.